SciSparc Ltd. (NASDAQ: SPRC) has successfully manufactured clinical batches of its drug candidate SCI-110 to be used in its upcoming multinational, multicenter, phase IIb trial for Tourette syndrome.

SCI-110 batches were manufactured by Procaps Group S.A., under Good Manufacturing Process conditions to comply with the U.S. Food and Drug Administration, the European Medicines Agency and Israeli Ministry of Health rigorous requirements.

The company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel. The company is currently preparing to submit a request for approval to the Institutional Review Board of Yale University, Connecticut, USA.

Tourette syndrome is a movement and neurobehavioral disorder characterized by chronic motor and vocal tics. With the onset …

Full story available on